Dawn Slown

About Dawn Slown

Dawn Slown is a research director in Market Strategies’ Life Sciences division. She is the day-to-day contact for all phases of research and is responsible for managing the project team. Dawn brings 15 years of experience in brand and communications research expertise to the company, with experience across many industries, but her focus has always been on pharma (consumer and Rx). She has contributed to award-winning creative campaigns, led countless communication testing programs and developed brand health tracking work to drive brand growth. Dawn earned a bachelor’s degree in advertising from Murray State University. In her free time, she enjoys traveling with her family, cooking from scratch and is an avid hockey, lacrosse, tennis, and equestrian fan (i.e., sports her children play).

Are PAPs the Panacea for What Ails Pharma Companies?

Are PAPs the Panacea for What Ails Pharma Companies?

Sixty percent of Americans suffer from a chronic disease, making the need for affordable treatment options critical. Even with health insurance, sufferers struggle to manage their condition as prescription costs continue to rise and shift to the patient. The repercussions of this trend cascade through the patient-provider relationship, which now includes insurance and pharmaceutical companies.

Market Strategies International recently conducted a study of more than 1,000 adults age 18 and older to understand the impact of rising prescription costs in three key areas:

  1. Intentional prescription non-compliance
  2. Consumer attitudes towards healthcare providers, health insurance providers and pharmaceutical companies
  3. Consumer awareness and enrollment in patient assistance programs (PAPs)

What we found is a huge gap between needs and value as well as a strong indication that PAPs may be the panacea for improving compliance and attitudes towards pharmaceutical companies.

Continue reading